Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Biotech Industry Analysis

UpdatedApr 01, 2026
DataAggregated Company Financials
Companies543
  • 7D3.2%
  • 3M3.6%
  • 1Y31.7%
  • YTDn/a

In the last week, the Biotech industry is up 3.2%, with AbbVie up 6.0%. This means that the industry has gained 32% over the past year. Earnings are forecast to grow by 23% annually.

Industry Valuation and Performance

Has the U.S. Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 01 Apr 2026US$1.3tUS$166.1b-US$11,559,502,547.9615.1x-108.5x7.5x
Fri, 27 Feb 2026US$1.4tUS$168.9b-US$14,126,668,051.5223x-96x8x
Sun, 25 Jan 2026US$1.3tUS$163.5b-US$15,173,296,321.8319.9x-83.6x7.8x
Tue, 23 Dec 2025US$1.2tUS$163.6b-US$15,776,154,626.6020.4x-78x7.5x
Thu, 20 Nov 2025US$1.2tUS$163.8b-US$16,250,245,666.1117.4x-74x7.3x
Sat, 18 Oct 2025US$1.2tUS$163.4b-US$18,206,487,321.4616.4x-63.6x7.1x
Mon, 15 Sep 2025US$1.1tUS$163.6b-US$18,376,778,364.5515.3x-58.4x6.6x
Wed, 13 Aug 2025US$1.0tUS$163.2b-US$15,585,333,681.1514.7x-65.4x6.2x
Fri, 11 Jul 2025US$985.4bUS$155.8b-US$23,408,172,286.8618.5x-42.1x6.3x
Sun, 08 Jun 2025US$951.2bUS$155.9b-US$23,930,730,032.6116.8x-39.7x6.1x
Tue, 06 May 2025US$957.9bUS$153.9b-US$24,808,548,995.6219.6x-38.6x6.2x
Thu, 03 Apr 2025US$777.4bUS$118.6b-US$37,150,082,180.2222.1x-20.9x6.6x
Sat, 01 Mar 2025US$838.5bUS$118.9b-US$37,247,148,694.9717x-22.5x7.1x
Mon, 27 Jan 2025US$981.2bUS$149.5b-US$26,320,970,275.6817.2x-37.3x6.6x
Wed, 25 Dec 2024US$967.2bUS$149.9b-US$26,389,155,679.4515.4x-36.7x6.5x
Fri, 22 Nov 2024US$996.8bUS$150.0b-US$26,773,538,404.2817.1x-37.2x6.6x
Sun, 20 Oct 2024US$908.0bUS$113.1b-US$35,950,283,773.0221.7x-25.3x8x
Tue, 17 Sep 2024US$932.2bUS$113.2b-US$35,921,970,608.8223.6x-26x8.2x
Thu, 15 Aug 2024US$874.6bUS$113.2b-US$36,248,323,495.6721.4x-24.1x7.7x
Sat, 13 Jul 2024US$1.2tUS$164.5b-US$28,119,687,665.6529.4x-42.2x7.2x
Mon, 10 Jun 2024US$1.2tUS$164.5b-US$26,798,622,131.2128.1x-43.1x7x
Wed, 08 May 2024US$1.1tUS$163.1b-US$27,148,218,752.3025.7x-41.4x6.9x
Fri, 05 Apr 2024US$1.1tUS$164.3b-US$23,437,244,791.3923.1x-48.9x7x
Sun, 03 Mar 2024US$1.2tUS$167.9b-US$21,319,237,627.7515.9x-56.5x7.2x
Tue, 30 Jan 2024US$1.4tUS$204.7b-US$22,656,479,710.0018.6x-63.1x7x
Thu, 28 Dec 2023US$1.4tUS$204.9b-US$22,182,372,574.0019.7x-62.7x6.8x
Sat, 25 Nov 2023US$1.2tUS$204.8b-US$22,015,480,281.0018.6x-55.7x6x
Mon, 23 Oct 2023US$1.2tUS$207.4b-US$13,059,770,915.0016.6x-93.9x5.9x
Wed, 20 Sep 2023US$1.3tUS$207.5b-US$12,859,428,048.0016.9x-99.9x6.2x
Fri, 18 Aug 2023US$1.3tUS$207.7b-US$12,279,921,044.0017.5x-103.5x6.1x
Sun, 16 Jul 2023US$1.1tUS$186.7b-US$15,968,283,125.0012.9x-71.1x6.1x
Tue, 13 Jun 2023US$1.2tUS$186.0b-US$15,957,784,646.0011.8x-72.2x6.2x
Thu, 11 May 2023US$1.2tUS$191.8b-US$11,888,575,254.0014.5x-97.7x6.1x
Sat, 08 Apr 2023US$1.2tUS$216.8b-US$5,729,503,829.0014x-203x5.4x
Price to Earnings Ratio

-203x


Total Market Cap: US$1.2tTotal Earnings: -US$5,729,503,829.00Total Revenue: US$216.8bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Biotech Industry Price to Earnings3Y Average -62.7x202420252026
Current Industry PE
  • Investors are optimistic on the American Biotechnology industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 6.8x is lower than the industry's current PS ratio of 7.5x.
Past Earnings Growth
  • The earnings for companies in the Biotechnology industry have deteriorated over the last three years.
  • Revenues have also declined 8.5% per year.
  • This means overall sales from these companies are declining and losses are subsequently expanding as well.

Industry Comparison

How does U.S. Biotech compare with similar industries?

US Market-0.61%
Healthcare1.34%
Biotech3.18%
Biotech3.18%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ABBV AbbVieUS$217.496.0%
+US$21.7b		5.4%PE91.9x
INSM InsmedUS$163.5210.3%
+US$3.3b		122.7%PS58.1x
REGN Regeneron PharmaceuticalsUS$772.644.2%
+US$3.2b		25.2%PE17.6x
APLS Apellis PharmaceuticalsUS$40.23133.5%
+US$2.9b		77.4%PE229.7x
UTHR United TherapeuticsUS$592.9811.5%
+US$2.7b		93.2%PE19.5x

Latest News

PEPG
US$1.77
PepGen
7D
-63.7%
1Y
21.2%
APLS
US$40.23
Apellis Pharmaceuticals
7D
133.5%
1Y
77.4%
VRDN
US$19.56
Viridian Therapeutics
7D
-28.1%
1Y
55.7%
ABBV
US$217.49
AbbVie
7D
6.0%
1Y
5.4%
UTHR
US$592.98
United Therapeutics
7D
11.5%
1Y
93.2%

UTHR: Pulmonary Fibrosis Promise Will Ultimately Fall Short Of Expectations

United Therapeutics' analyst fair value estimate has shifted from $423 to $471 as analysts factor in recent TETON-1 and ralinepag data, updated profit margin assumptions, and a modestly higher future P/E. Analyst Commentary Street research around United Therapeutics has become more focused on the readthrough from TETON-1 in idiopathic pulmonary fibrosis, the Phase 3 ralinepag results in pulmonary arterial hypertension, and the planned soft mist inhaler for treprostinil.
AMGN
US$351.85
Amgen
7D
-0.6%
1Y
15.1%

AMGN: Obesity And Cardiovascular Pipeline Will Support Future Cash Generation

Analysts kept the $432 price target for Amgen steady, reflecting a balance between recent target increases tied to pipeline and commercial updates, and newer Hold and Equal Weight initiations that describe the shares as fairly valued after a strong run. Analyst Commentary Recent research on Amgen shows a mix of optimism and caution around valuation, with bullish analysts highlighting commercial execution and the expanding pipeline, while newer initiations frame the shares as fairly valued after a strong move higher.
MDGL
US$523.47
Madrigal Pharmaceuticals
7D
17.6%
1Y
61.6%

MDGL: MASH Combinations And Cirrhosis Expansion Will Shape Balanced Future Outlook

Analysts now set a consolidated price target for Madrigal Pharmaceuticals at $529, down from previous levels such as $570, reflecting updated forecasts around gross-to-net adjustments, even as model assumptions for revenue growth, profit margins, and future P/E remain broadly consistent. Analyst Commentary Recent research updates on Madrigal Pharmaceuticals show a mix of support and caution, with several bearish analysts rethinking how much upside is left after the stock's strong prior move and the latest company updates.
ONC
US$296.97
BeOne Medicines
7D
7.7%
1Y
9.6%
ANAB
US$55.46
AnaptysBio
7D
-15.2%
1Y
192.4%
SMMT
US$18.96
Summit Therapeutics
7D
22.0%
1Y
0.9%
IBRX
US$7.67
ImmunityBio
7D
-5.0%
1Y
151.5%
CAI
US$17.88
Caris Life Sciences
7D
-7.1%
1Y
n/a
DNLI
US$19.20
Denali Therapeutics
7D
-14.6%
1Y
39.7%
REGN
US$772.64
Regeneron Pharmaceuticals
7D
4.2%
1Y
25.2%
INSM
US$163.52
Insmed
7D
10.3%
1Y
122.7%
VRTX
US$446.54
Vertex Pharmaceuticals
7D
-0.5%
1Y
-7.9%

VRTX: Renal Trial Success And Nephrology Pipeline Will Drive Next Phase

Vertex Pharmaceuticals' analyst fair value estimate has moved from $504.04 to $547.72. Analysts point to higher modeled revenue growth, slightly stronger profit margins, a richer future P/E assumption, and a wave of Street price target hikes tied to positive povetacicept Phase 3 RAINIER data and the growing nephrology pipeline.